INmune Bio Plunges 14.7% on Widening Losses

INmune Bio's stock price plummeted by 14.7% in pre-market trading on August 8, 2025, marking a significant decline for the biotechnology company.

INmune Bio reported a substantial increase in its second-quarter loss, widening by 110% compared to the same period last year. The company continues to operate without generating meaningful revenue, which is typical for its current clinical-stage status. As of June, INmune Bio's cash and cash equivalents stood at $33.4 million, providing a financial cushion as it navigates through its development phases.

The widening loss can be attributed to the company's ongoing investment in research and development, as it seeks to advance its pipeline of therapeutic candidates. Despite the financial setback, INmune Bio remains focused on its mission to develop innovative treatments for neurological and inflammatory diseases.

Investors and analysts will be closely monitoring the company's progress in its clinical trials and its ability to secure additional funding to support its operations. The significant drop in stock price reflects the market's concern over the company's financial performance and its ability to generate revenue in the near future.